Chief executive Cheryl Maley said the year brought advances in the company’s lead radiopharmaceutical program, new strategic partnerships, and further validation of DEP technology's potential in targeted cancer treatment.
Starpharma narrows loss as Genentech deal lifts revenue and new funding extends runway
August 26, 2026 Australian Biotech
Latest Video
New Stories
-
Noxopharm pushes Sofra platform towards cancer proof of concept
August 26, 2026 - - Australian Biotech -
Argent BioPharma takes CannEpil into US veterinary regulatory process
August 26, 2026 - - Latest News -
Entropy takes TRP-8803 to the US in head-to-head depression trial
August 26, 2026 - -
Neuren’s first dividend signals a new phase built on DAYBUE royalties
August 26, 2026 - - Australian Biotech -
Starpharma narrows loss as Genentech deal lifts revenue and new funding extends runway
August 26, 2026 - - Australian Biotech -
Genetic Signatures and Microba explore merger to build infectious disease diagnostics group
August 26, 2026 - - Australian Biotech -
Australian company secures European approval for rare disease treatment
August 26, 2026 - - Latest News

